Sareptein, a drug for muscular dystrophy, has seen its stock price plummet due to a crisis that worsened over time. The biotech company is facing several challenges, including manufacturing issues and regulatory concerns.
In 2018, Sareptein was approved by the FDA as a treatment for Duchenne muscular dystrophy. However, since then, reports of side effects have increased, raising questions about its safety. Moreover, production delays and quality control issues have affected supply chains, causing prices to rise and demand to decline.
The crisis began with allegations that Sareptein was being produced in a plant with a history of contamination issues. This led to a recall and a halt in shipments to some countries. As the situation unfolded, more concerns emerged regarding the company’s manufacturing processes.
Sareptein’s stock price has fallen by over 70% since its peak in 2018. The decline is attributed to investor concerns about the company’s ability to resolve the crisis and maintain production quality.
Source: https://www.barrons.com/articles/sarepta-stock-crisis-fda-fcc18829